"This panel will focus on the dramatic shift in the law of patent obviousness following the Supreme Court's landmark decision earlier this year in KSR v. Teleflex (as well as several significant Federal Circuit decisions addressing the scope of obviousness in biopharma cases) and the potentially significant implications of that shift for research-focused biotech and pharmaceutical companies. Chief IP counsel at major biotech and pharmaceutical institutions will discuss their perspectives on the changes in the law and how it affects IP prosecution and litigation strategies. The panel will examine what can be done to ensure that innovation is rewarded appropriately in the face of increased judicial and legislative scrutiny of the scope of patent protection."

Objective1:Examine product life-cycle management considerations.

Objective2:Discuss patent prosecution and litigation strategy including assessing what types of patents are most vulnerable to obviousness challenge.

Objective3:Address the question: Is there a legislative fix?